Euronews is no longer accessible on Internet Explorer. This browser is not updated by Microsoft and does not support the last technical evolutions. We encourage you to use another browser, such as Edge, Safari, Google Chrome or Mozilla Firefox.



AstraZeneca's blood cancer drug meets main goal in late-stage trial

AstraZeneca's blood cancer drug meets main goal in late-stage trial
FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid/File Photo -
Brendan McDermid(Reuters)
Text size Aa Aa

(Reuters) – AstraZeneca Plc said on Thursday its blood cancer drug met the primary endpoint of a final stage trial, the second success for the treatment in a month.

The drug, Calquence, showed meaningful improvement in patients with lymphocytic leukaemia when compared with a chemotherapy-based treatment, the company said.

Calquence, which is already approved by the U.S. drug regulator to treat a rare type of blood cancer, also met the primary endpoint in a trial in May testing the drug in comparison with available treatment.

(Reporting by Sangameswaran S in Bengaluru; Editing by Saumyadeb Chakrabarty)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on for a limited time.